journal article·2023-10

Targeted heart repair by Tβ4-loaded cardiac-resident macrophage-derived extracellular vesicles modified with monocyte membranes

Peier Chen, Yuxuan Pan, Xiaodong Ning, Xu Shi, Jianfeng Zhong, Xianglin Fan, Weirun Li, Yintong Teng, Xueting Liu, Bin Yu, Yanhua Yang, Hekai Li, Caiwen Ou

Acta Biomaterialia· Volume 169
Publisher page

Abstract

Recent studies have demonstrated the critical role of cardiac-resident macrophages (cMacs) in the maintenance of physiological homeostasis. However, recruitment of circulating monocyte-derived macrophages decreases cMac levels post-myocardial infarction (MI). Transplanting cMacs is not an ideal option due to their low survival rates and the risk of immunological rejection. However, extracellular vesicle therapy has the potential to provide a feasible and safe alternative for cardiac repair. In this study, cell membrane-modified extracellular vesicles (MmEVs) were developed for heart repair by modifying cMac-derived extracellular vesicles (mEVs) with monocyte membranes, resulting in immune evasion and sequential targeted localization to damaged regions through expression of CD47 on MmEVs and strong affinity between monocyte membrane proteins and CCL2. Additionally, to fully exploit the potential clinical application of MmEVs and achieve a better curative effect, thymosin β4 (Tβ4) was loaded into the nanoparticles, resulting in Tβ4-MmEVs. In vitro experiments indicated that both the MmEVs and Tβ4-MmEVs promoted cardiomyocyte proliferation and endothelial cell migration. Animal experiments suggested that MI mice treated with MmEVs and Tβ4-MmEVs exhibited reduced myocardial fibrosis and increased vascular density compared to the control group. Thus, we posit that these targeted nanoparticles hold significant potential for MI adjuvant therapy and may open new avenues for cardiac repair and regeneration. STATEMENT OF SIGNIFICANCE: Extracellular vesicles (EVs) derived from bioactive parent cell sources involved in pathological and repair processes for cardiovascular disease have emerged as a compelling strategy for regenerative therapy. In this study, we constructed monocyte membrane-modified extracellular vesicles loaded with a drug (Tβ4-MmEVs) for heart repair that exhibit extraordinary abilities of immune evasion and sequential localization to damaged regions owing to the presence of CD47 and the strong affinity between monocytes and damaged cardiomyocytes and endothelial cells. The bioactivities of Tβ4-MmEVs on enhancing cardiomyocyte and endothelial cell proliferation were validated both in vitro and in vivo. Effective development and implementation of therapeutically membrane-modified nanoparticles from homologous origins can provide a reference for adjuvant therapy in clinical MI management.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Extracellular vesicles in disease · Cardiac Fibrosis and Remodeling · Tissue Engineering and Regenerative Medicine

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (51)

Show source-provided references
1. Acute myocardial infarction10.1016/S0140-6736(03)12712-2 ↗
2. Acute myocardial infarction10.1056/NEJMra1606915 ↗
3. Immune and inflammatory networks in myocardial infarction: current research and its potential implications for the clinic10.3390/ijms23095214 ↗
4. Origins, biology, and diseases of tissue macrophages10.1146/annurev-immunol-093019-111748 ↗
5. Primitive embryonic macrophages are required for coronary development and maturation10.1161/CIRCRESAHA.115.308270 ↗
6. Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart10.1073/pnas.1406508111 ↗
7. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation10.1016/j.immuni.2013.11.019 ↗
8. Macrophages are required for neonatal heart regeneration10.1172/JCI72181 ↗
9. Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction10.1038/s41590-018-0272-2 ↗
10. Tissue resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury10.1161/CIRCRESAHA.118.314028 ↗
11. Diversity, mechanisms, and significance of macrophage plasticity10.1146/annurev-pathmechdis-012418-012718 ↗
12. Recruited macrophages that colonize the post-inflammatory peritoneal niche convert into functionally divergent resident cells10.1038/s41467-021-21778-0 ↗
13. Exosomes: the next generation of endogenous nanomaterials for advanced drug delivery and therapy10.1016/j.actbio.2018.12.045 ↗
14. Pro-angiogenic macrophage phenotype to promote myocardial repair10.1016/j.jacc.2019.03.503 ↗
15. gp130 controls cardiomyocyte proliferation and heart regeneration10.1161/CIRCULATIONAHA.119.044484 ↗
16. Targeted delivery of extracellular vesicles in heart injury10.7150/thno.51571 ↗
17. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes10.1016/j.jconrel.2014.12.013 ↗
18. Advances in analysis of biodistribution of exosomes by molecular imaging10.3390/ijms21020665 ↗
19. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter10.1021/nn404945r ↗
20. Biodistribution of intratracheal, intranasal, and intravenous injections of human mesenchymal stromal cell-derived extracellular vesicles in a mouse model for drug delivery studies
21. Neutrophil membrane engineered HucMSC sEVs alleviate cisplatin-induced AKI by enhancing cellular uptake and targeting10.1186/s12951-022-01574-8 ↗
22. Neuronal mitochondria-targeted delivery of curcumin by biomimetic engineered nanosystems in Alzheimer's disease mice10.1016/j.actbio.2020.03.029 ↗
23. Monocyte mimics improve mesenchymal stem cell-derived extracellular vesicle homing in a mouse MI/RI model10.1016/j.biomaterials.2020.120168 ↗
24. Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications10.7150/thno.47841 ↗
25. Targeted therapy for peri-prosthetic osteolysis using macrophage membrane-encapsulated human urine-derived stem cell extracellular vesicles10.1016/j.actbio.2023.02.003 ↗
26. Regulation of type 2 immunity in myocardial infarction10.3389/fimmu.2019.00062 ↗
27. Exosomes as potential functional nanomaterials for tissue engineering
28. Injectable hydrogels for sustained delivery of extracellular vesicles in cartilage regeneration10.1016/j.jconrel.2023.01.060 ↗
29. Nanoengineering facilitating the target mission: targeted extracellular vesicles delivery systems design10.1186/s12951-022-01638-9 ↗
30. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer10.1016/j.actbio.2019.10.022 ↗
31. Controlled release of thymosin β4 using collagen-chitosan composite hydrogels promotes epicardial cell migration and angiogenesis10.1016/j.jconrel.2011.05.026 ↗
32. Thymosin β4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of human induced-pluripotent stem cell-derived cardiomyocytes in a porcine model of acute myocardial infarction10.7150/thno.56757 ↗
33. Ion therapy: a novel strategy for acute myocardial infarction
34. Cardiac macrophages prevent sudden death during heart stress10.1038/s41467-021-22178-0 ↗
35. Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction
36. Exosomes from mesenchymal stem cells overexpressing MIF enhance myocardial repair10.1002/jcp.29456 ↗
37. Platelet membrane and stem cell exosome hybrid enhances cellular uptake and targeting to heart injury
38. Neutrophils enable local and non-invasive liposome delivery to inflamed skeletal muscle and ischemic heart10.1002/adma.202003598 ↗
39. Active cargo loading into extracellular vesicles: highlights the heterogeneous encapsulation behaviour
40. Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization10.1002/adma.201606209 ↗
41. Injectable AuNP-HA matrix with localized stiffness enhances the formation of gap junction in engrafted human induced pluripotent stem cell-derived cardiomyocytes and promotes cardiac repair10.1016/j.biomaterials.2021.121231 ↗
42. Exosome biochemistry and advanced nanotechnology for next-generation theranostic platforms
43. Fabrication of Tβ4-Exosome-releasing artificial stem cells for myocardial infarction therapy by improving coronary collateralization10.1016/j.bioactmat.2022.01.029 ↗
44. CCR2+ monocyte-derived infiltrating macrophages are required for adverse cardiac remodeling during pressure overload
45. Cardioimmunology: the immune system in cardiac homeostasis and disease10.1038/s41577-018-0065-8 ↗
46. Platelet-mimicking nanoparticles co-loaded with W18O49 and metformin alleviate tumor hypoxia for enhanced photodynamic therapy and photothermal therapy10.1016/j.actbio.2018.09.017 ↗
47. Embryonic stem cells-derived exosomes endowed with targeting properties as chemotherapeutics delivery vehicles for glioblastoma therapy
48. Extracellular vesicles as bioactive nanotherapeutics: an emerging paradigm for regenerative medicine10.7150/thno.72812 ↗
49. Hybrid cell membrane-coated nanoparticles: a multifunctional biomimetic platform for cancer diagnosis and therapy10.1016/j.actbio.2020.05.028 ↗
50. A combined “eat me/don't eat me” strategy based on extracellular vesicles for anticancer nanomedicine
51. Hyaluronan receptor LYVE-1-expressing macrophages maintain arterial tone through hyaluronan-mediated regulation of smooth muscle cell collagen10.1016/j.immuni.2018.06.008 ↗